Key Takeaways
- • Waypoint Bio closed a $20 million Series A financing round led by Amplify Partners, with participation from General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, and existing investor Hummingbird Ventures.
- • The AI-native biotech company is developing next-generation CAR T therapies for solid tumors using spatial biology, artificial intelligence, and computer vision integrated into a proprietary platform.
- • Waypoint's lead program pairs an in vivo CAR T asset with a proprietary next-generation lentiviral vector, targeting clinical entry in China in late 2026.
- • Elliot Hershberg, representing lead investor Amplify Partners, will join the company's board of directors.
- • The Series A funding positions Waypoint to expand its AI-designed therapeutics platform into additional biologics and therapeutic areas beyond its current CAR T focus.
Summary
Waypoint Bio, a New York-based AI-native biotech company, announced the closure of a $20 million Series A financing round, marking a significant capital raise for the emerging spatial biology platform company. Amplify Partners led the round, with General Catalyst, Time BioVentures, Mitsui Global Investments, and Lux Capital as new institutional investors, alongside existing shareholder Hummingbird Ventures. Elliot Hershberg, representing Amplify Partners, will assume a board seat at the company.
The company's core technology integrates artificial intelligence, computer vision, and spatial pooled screening to design next-generation therapeutics. Waypoint's initial focus centers on developing CAR T cell therapies targeting solid tumors—an area where previous generations of CAR T cells have faced significant clinical challenges. The company's lead program combines an in vivo CAR T asset with a proprietary next-generation lentiviral vector platform, representing a dual innovation approach to enhance therapeutic efficacy and manufacturability.
Waypoint's development roadmap includes clinical entry for its lead program in China targeted for late 2026, providing a near-term inflection point for the platform's validation. The Series A capital will support advancement of the lead program toward this clinical milestone while enabling the company to extend its AI-designed therapeutics platform into additional biologics applications and expand beyond CAR T into adjacent therapeutic areas. This strategic expansion mirrors broader industry trends toward platform technologies that leverage computational biology to address multiple disease indications.
The company's core technology integrates artificial intelligence, computer vision, and spatial pooled screening to design next-generation therapeutics. Waypoint's initial focus centers on developing CAR T cell therapies targeting solid tumors—an area where previous generations of CAR T cells have faced significant clinical challenges. The company's lead program combines an in vivo CAR T asset with a proprietary next-generation lentiviral vector platform, representing a dual innovation approach to enhance therapeutic efficacy and manufacturability.
Waypoint's development roadmap includes clinical entry for its lead program in China targeted for late 2026, providing a near-term inflection point for the platform's validation. The Series A capital will support advancement of the lead program toward this clinical milestone while enabling the company to extend its AI-designed therapeutics platform into additional biologics applications and expand beyond CAR T into adjacent therapeutic areas. This strategic expansion mirrors broader industry trends toward platform technologies that leverage computational biology to address multiple disease indications.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.